a | ||||||
 | DL 1 4 mg/kg N = 3 | DL 2 8 mg/kg N = 3 | DL 3 16 mg/kg N = 3 | DL 4 32 mg/kg N = 6 | Overall N = 15 | |
Stable disease (N, %) | 3 (100%) | 2 (67%) | 2 (67%) | 4 (67%) | 11 (73%) | |
Progressive disease (N, %) | 0 (0%) | 1 (33%) | 1 (33%) | 2 (33%) | 4 (27%) | |
b | ||||||
Patient # | Tumor type | Dose (mg/kg) | Time on study (months)* | Best response | Off treatment reason | IL-8 level decrease |
1 | Colorectal | 4 | 3.5 | SD | Patient choice | Â |
2 | Prostate | 4 | 2 | SD | Patient choice | x |
3 | Chordoma | 4 | 8 | SD | Patient choice | Â |
4 | Chordoma | 8 | 13 | SD | Patient choice | Â |
5 | Colorectal | 8 | 1.5 | PD | Progression | Â |
6 | Esophageal | 8 | 7 | SD | Progression | x |
7 | Chondrosarcoma | 16 | 1 | PD | Progression | x |
8 | Chordoma | 16 | 5.5 | SD | Progression | Â |
9 | Chordoma | 16 | 5.5 | SD | Patient choice | x |
10 | Papillary thyroid | 32 | 5.5 | SD | Patient choice | x |
11 | Colorectal | 32 | 4.5 | SD | Patient choice | x |
12 | Prostate | 32 | 8 | SD | Patient choice | x |
13 | Colorectal | 32 | 7 | SD | Patient choice | x |
14 | Ovarian | 32 | 1.5 | PD | Progression | x |
15 | Chordoma | 32 | 2 | PD | Progression | x |